1. Medtech Insight
  2. >>Policy & Regulation

Latest Coronavirus Bill Passage Adds $100Bn To National Testing Effort

 
• By Sue Darcey

With US House passage of a $484bn coronavirus relief package late on 23 April, Congress has allocated another substantial chunk of funding to support nationwide COVID-19 testing. President Trump signed the bill midday on 24 April.

Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA,

Both houses of Congress have now passed, and President Trump signed on 24 April, a $484bn COVID-19 relief package that will dramatically ramp up testing for the virus across the US. $100bn will go to greater testing efforts and to reimburse Medicare and Medicaid suppliers that have already been fighting the coronavirus, and the balance will be used for loans to help out small businesses that have been economically wiped out by nationwide forced shutdowns of wholesale and retail establishments.

A total of 394 members of Congress – most wearing protective masks during floor debate – were able to fly, drive or catch a train back to Washington, DC, from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.